View More View Less
  • 1 Semmelweis Egyetem, Fogorvostudományi Kar, Budapest, Üllői út 26., 1085
Open access

Absztrakt:

A gyógyszer indukálta osteonecrosis antireszorptív terápia szövődményeként léphet fel, kezelése komoly kihívást jelent. A betegség 2003. évi leírását követően a gyógyszer indukálta osteonecrosis kialakulásában szerepet játszó szisztémás és lokális rizikófaktorokat gyűjtöttük össze. A rizikófaktorokat a PubMed-adatbázisban az 1998 és 2018 közötti időszakban megjelent irodalmi kutatások alapján rendszereztük. A kockázattal élő pácienseink három csoportja: antireszorptív terápiát még nem megkezdettek, már antireszorptív terápiában részesülők, manifeszt osteonecrosisban szenvedők. A fogorvos feladata a rizikófaktorok felmérése, ennek megfelelő kezelési terv felállítása, a kontrollvizsgálatok gyakoriságának megszabása. Az antireszorptív terápiák közül az onkológiai indikációval kapott intravénás kezelés jelenti a legnagyobb kockázatot. További szisztémás rizikófaktorok: járulékos terápia, kísérő betegség, életmód, személyi tényezők. A lokális rizikófaktorok a következők: dentoalveolaris sebészi beavatkozás, periapicalis és parodontalis gyulladások, rosszul illeszkedő kivehető fogpótlások, anatómiai eltérések. A rizikófaktorok halmozódása határozza meg a necrosis kialakulásának valószínűségét. Az osteonecrosis kialakulásának akkor a legkisebb a valószínűsége, ha a beteg a biszfoszfonátterápiát szanált fogazati statusszal kezdi meg. Orv Hetil. 2019; 160(7): 243–251.

If the inline PDF is not rendering correctly, you can download the PDF file here.

  • 1

    Reszka AA, Rodan GA. Nitrogen-containing bisphosphonate mechanism of action. Mini Rev Med Chem. 2004; 4: 711–719.

  • 2

    Hall A. Rho GTPases and the actin cytoskeleton. Science 1998; 279: 509–514.

  • 3

    Luckman SP, Hughes DE, Coxon FP, et al. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res. 1998; 13: 581–589.

  • 4

    Russell RG. Bisphosphonates: from bench to bedside. Ann N Y Acad Sci. 2006; 1068: 367–401.

  • 5

    Hanley DA, Adachi JD, Bell A, et al. Denosumab: mechanism of action and clinical outcomes. Int J Clin Pract. 2012; 66: 1139–1146.

  • 6

    Soós B, Vajta L, Szalma J. Sunitinib and zoledronic acid induced osteonecrosis of the jaw. [Sunitinib és zoledronsav által indukált állcsont-osteonecrosis.] Orv Hetil. 2015; 156: 1865–1870. [Hungarian]

  • 7

    Janovszky Á, Vereb T, Szabó A. et al. Current approaches for early detection and treatment of medication-related osteonecrosis of jaw. [Aktuális trendek a gyógyszer indukálta állcsontnecrosis korai felismerése és kezelési stratégiája terén.] Orv Hetil. 2014; 155: 1960–1966. [Hungarian]

  • 8

    Magyar Arc-, Állcsont- és Szájsebészeti Társaság, Magyar Osteoporosis és Osteoarthrológiai Társaság, Magyar Onkológusok Társasága, Magyar Reumatológusok Egyesülete, Magyar Ortopéd Társaság. Bisphosphonate-induced jaw osteonecrosis – prevention and treatment. [A biszfoszfonátok által indukált állcsont-osteonecrosisok megelőzése és kezelése.] Orv Hetil. 2010; 151: 148–149. [Hungarian]

  • 9

    Vescovi P, Campisi G, Fusco V, et al. Surgery-triggered and non surgery-triggered bisphosphonate-related osteonecrosis of the jaws (BRONJ): a retrospective analysis of 567 cases in an Italian multicenter study. Oral Oncol. 2011; 47: 191–194.

  • 10

    Bamias A, Kastritis E, Bamia C, et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol. 2005; 23: 8580–8587.

  • 11

    Ruggiero SL, Dodson TB, Fantasia J, et al. American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw – 2014 update. J Oral Maxillofac Surg. 2014; 72: 1938–1956.

  • 12

    Qi WX, Tang LN, He AN, et al. Risk of osteonecrosis of the jaw in cancer patients receiving denosumab: a meta-analysis of seven randomized controlled trials. Int J Clin Oncol. 2014; 19: 403–410.

  • 13

    Smith MR, Saad F, Coleman R, et al. Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial. Lancet 2012; 379: 39–46.

  • 14

    Gaudin E, Seidel L, Bacevic M, et al. Occurrence and risk indicators of medication-related osteonecrosis of the jaw after dental extraction: a systematic review and meta-analysis. J Clin Periodontol. 2015; 42: 922–932.

  • 15

    Badros A, Weikel D, Salama A, et al. Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors. J Clin Oncol. 2006; 24: 945–952.

  • 16

    Palaska PK, Cartsos V, Zavras AI. Bisphosphonates and time to osteonecrosis development. Oncologist 2009; 14: 1154–1166.

  • 17

    Di Fede O, Fusco V, Matranga D, et al. Osteonecrosis of the jaws in patients assuming oral bisphosphonates for osteoporosis: a retrospective multi-hospital-based study of 87 Italian cases. Eur J Intern Med. 2013; 24: 784–790.

  • 18

    Jadu F, Lee L, Pharoah M, et al. A retrospective study assessing the incidence, risk factors and comorbidities of pamidronate-related necrosis of the jaws in multiple myeloma patients. Ann Oncol. 2007; 18: 2015–2019.

  • 19

    Chiu CT, Chiang WF, Chuang CY, et al. Resolution of oral bisphosphonate and steroid-related osteonecrosis of the jaw – a serial case analysis. J Oral Maxillofac Surg. 2010; 68: 1055–1063.

  • 20

    Van Cann T, Loyson T, Verbiest A. Incidence of medication-related osteonecrosis of the jaw in patients treated with both bone resorption inhibitors and vascular endothelial growth factor receptor tyrosine kinase inhibitors. Support Care Cancer 2018; 26: 869–878.

  • 21

    Vaszilko M, Kovacs E, Restar L, et al. Potential significance of antiestrogen therapy in the development of bisphosphonate related osteonecrosis of the jaw. J Craniomaxillofac Surg. 2014; 42: 1932–1936.

  • 22

    Campisi G, Lo Russo L, Agrillo A, et al. BRONJ expert panel recommendation of the Italian Societies for Maxillofacial Surgery (SICMF) and Oral Pathology and Medicine (SIPMO) on Bisphosphonate-Related Osteonecrosis of the Jaws: risk assessment, preventive strategies and dental management. J Maxillofac Surg. 2011; 22: 103–124.

  • 23

    Wessel JH, Dodson TB, Zavras AI. Zoledronate, smoking, and obesity are strong risk factors for osteonecrosis of the jaw: a case-control study. J Oral Maxillofac Surg. 2008; 66: 625–631.

  • 24

    Yang G, Hamadeh IS, Katz J, et al. SIRT1/HERC4 locus associated with bisphosphonate-induced osteonecrosis of the jaw: an exome-wide association analysis. J Bone Miner Res. 2018; 33: 91–98.

  • 25

    Vaszilko M, Barabás J, Szabó Gy, et al. Osteonecrosis of the jaws by using bisphosponates. [Biszfoszfonátok alkalmazása következtében kialakuló osteonecrosis az állcsontokban.] Fogorv Szle. 2007; 100: 115–119. [Hungarian]

  • 26

    Vahtsevanos K, Kyrgidis A, Verrou E, et al. Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw. J Clin Oncol. 2009; 27: 5356–5362.

  • 27

    McGowan K, McGowan T, Ivanovski S. Risk factors for medication-related osteonecrosis of the jaws: A systematic review. Oral Dis. 2018; 24: 527–536.

  • 28

    Association of Hungarian Medical Societies. The prevention and treatment of bisphosphonate-induced osteonecrosis of the jaw II. [Magyar Orvostársaságok és Egyesületek Szövetsége. A biszfoszfonátok által indukált állcsont oszteonekrózisok megelőzése és kezelése II.] Fogorv Szle. 2014; 107: 106–107. [Hungarian]

  • 29

    Marx RE, Sawatari Y, Fortin M, et al. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg. 2005; 63: 1567–1575.

  • 30

    Katz H. Endodontic implications of bisphosphonate-associated osteonecrosis of the jaws: a report of three cases. J Endod. 2005; 31: 831–834.

  • 31

    Moinzadeh AT, Shemesh H, Neirynck NA, et al. Bisphosphonates and their clinical implications in endodontic therapy. Int Endod J. 2013; 46: 391–398.

  • 32

    Filleul O, Crompot E, Saussez S. Bisphosphonate-induced osteonecrosis of the jaw: a review of 2,400 patient cases. J Cancer Res Clin Oncol. 2010; 136: 1117–1124.

  • 33

    Migliorati CA, Mattos K, Palazzolo MJ. How patients’ lack of knowledge about oral bisphosphonates can interfere with medical and dental care. J Am Dent Assoc. 2010; 141: 562–566.

  • 34

    Campisi G, Di Fede O, Musciotto A, et al. Bisphosphonate-related osteonecrosis of the jaw (BRONJ): run dental management designs and issues in diagnosis. Ann Oncol. 2007; 18(Suppl 6): vi168– vi172.

  • 35

    Otto S, Pautke C, Van den Wyngaert T, et al. Medication-related osteonecrosis of the jaw: prevention, diagnosis and management in patients with cancer and bone metastases. Cancer Treat Rev. 2018; 69: 177–187.

  • 36

    Khan SA, Kanis JA, Vasikaran S, et al. Elimination and biochemical responses to intravenous alendronate in postmenopausal osteoporosis. J Bone Miner Res. 1997; 12: 1700–1707.

  • 37

    Kyrgidis A, Vahtsevanos K, Koloutsos G, et al. Bisphosphonate-related osteonecrosis of the jaws: a case–control study of risk factors in breast cancer patients. J Clin Oncol. 2008; 26: 4634–4638.

  • 38

    Woo SB, Hellstein JW, Kalmar JR. Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med. 2006; 144: 753–761.

  • 39

    Henry DH, Costa L, Goldwasser F, et al. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol. 2011; 29: 1125–1132.

  • 40

    Saad F, Brown JE, Van Poznak C, et al. Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases. Ann Oncol. 2012; 23: 1341–1347.

  • 41

    Lo JC, O’Ryan FS, Gordon NP, et al. Prevalence of osteonecrosis of the jaw in patients with oral bisphosphonate exposure. J Oral Maxillofac Surg. 2010; 68: 243–253.

  • 42

    United States Food and Drug Administration. Background Document for Meeting of Advisory Committee for Reproductive Health Drugs and Drug Safety and Risk Management Advisory Committee. Silver Spring, MD, September 9, 2011. Available from: Committees/CommitteesMeetingMaterials/drugs/DrugSafetyandRiskManagementAdvisoryCommittee/ucm270958.pdf [accessed: February 10, 2014].

  • 43

    Dereci Ö, Orhan EO, Irmak Ö, et al. The effect of the duration of intravenous zolendronate medication on the success of non-surgical endodontic therapy: a retrospective study. BMC Oral Health 2016; 16: 9.

  • 44

    Ruggiero S, Gralow J, Marx RE, et al. Practical guidelines for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in patients with cancer. J Oncol Pract. 2006; 2: 7–14.

  • 45

    Lodi G, Sardella A, Salis A, et al. Tooth extraction in patients taking intravenous bisphosphonates: a preventive protocol and case series. J Oral Maxillofac Surg. 2010; 68: 107–110.

  • 46

    Yoneda T, Hagino H, Sugimoto T, et al. Bisphosphonate-related osteonecrosis of the jaw: position paper from the Allied Task Force Committee of Japanese Society for Bone and Mineral Research, Japan Osteoporosis Society, Japanese Society of Periodontology, Japanese Society for Oral and Maxillofacial Radiology, and Japanese Society of Oral and Maxillofacial Surgeons. J Bone Miner Metab. 2010, 28: 365–383.

  • 47

    Gallego L, Junquera L, Pelaz A, et al. Rubber dam clamp trauma during endodontic treatment: a risk factor of bisphosphonate-related osteonecrosis of the jaw? J Oral Maxillofac Surg. 2011; 69: e93–e95.

  • 48

    American Dental Association Council on Scientific Affairs. Dental management of patients receiving oral bisphosphonate therapy: expert panel recommendations. J Am Dent Assoc. 2006; 137: 1144–1150.

  • 49

    Göllner M, Holst S, Fenner M, et al. Prosthodontic treatment of a patient with bisphosphonate-induced osteonecrosis of the jaw using a removable dental prosthesis with a heat-polymerized resilient liner: a clinical report. J Prosthet Dent. 2010; 103: 196–201.

  • 50

    Marx RE, Cillo JE Jr, Ulloa JJ. Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment. J Oral Maxillofac Surg. 2007; 65: 2397–2410.